Compare LSBK & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSBK | PEPG |
|---|---|---|
| Founded | 1891 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 121.7M |
| IPO Year | 2025 | 2022 |
| Metric | LSBK | PEPG |
|---|---|---|
| Price | $17.11 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.17 |
| AVG Volume (30 Days) | 7.8K | ★ 1.1M |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 49.23 | 25.61 |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $65.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.14 | $1.01 |
| 52 Week High | $17.96 | $7.80 |
| Indicator | LSBK | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 38.93 |
| Support Level | $16.64 | $1.47 |
| Resistance Level | $17.56 | $1.96 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 70.34 | 1.09 |
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.